Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–47.
Article
CAS
PubMed
Google Scholar
Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25–32.
Article
CAS
PubMed
Google Scholar
Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17:2–10.
Article
CAS
PubMed
Google Scholar
Carlsson M, Berntorp E, Bjorkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia. 1997;3:96–101.
Article
CAS
PubMed
Google Scholar
Lindvall K, Astermark J, Bjorkman S, Ljung R, Carlsson KS, Persson S, Berntorp E. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia. 2012;18:855–9.
Article
CAS
PubMed
Google Scholar
Verma SP, Dutta TK, Mahadevan S, Nalini P, Basu D, Biswal N, Ramesh A, Charles D, Vinod KV, Harichandra Kumar KT. A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country. Haemophilia. 2016;22:342–8.
Article
CAS
PubMed
Google Scholar
St-Louis J, Urajnik DJ, Menard F, Cloutier S, Klaassen RJ, Ritchie B, Rivard GE, Warner M, Blanchette V, Young NL. Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada. BMC Hematol. 2016;16:13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Feldman BM, Funk SM, Bergstrom BM, Zourikian N, Hilliard P, van der Net J, Engelbert R, Petrini P, van den Berg HM, Manco-Johnson MJ, et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken). 2011;63:223–30.
Article
Google Scholar
Ware JE, Kosinsk IM, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User's manual for the sf-36v2tm health survey. 2nd ed. Lincoln: QualityMetric Incorporated; 2007.
Google Scholar
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–44.
Article
CAS
PubMed
Google Scholar
Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10:359–67.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tagliaferri A, Franchini M, Coppola A, Rivolta GF, Santoro C, Rossetti G, Feola G, Zanon E, Dragani A, Iannaccaro P, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia. 2008;14:945–51.
Article
CAS
PubMed
Google Scholar
van den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, Nieuwenhuis HK. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol. 2001;112:561–5.
Article
PubMed
Google Scholar
Tagliaferri A, Feola G, Molinari AC, Santoro C, Rivolta GF, Cultrera DB, Gagliano F, Zanon E, Mancuso ME, Valdre L, et al. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb Haemost. 2015;114:35–45.
Article
PubMed
Google Scholar
Oldenburg J, Zimmermann R, Katsarou O, Theodossiades G, Zanon E, Niemann B, Kellermann E, Lundin B. Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. Haemophilia. 2015;21:171–9.
Article
CAS
PubMed
Google Scholar
Wu R, Luke KH, Poon MC, Wu X, Zhang N, Zhao L, Su Y, Zhang J. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia. 2011;17:70–4.
Article
CAS
PubMed
Google Scholar
Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9:700–10.
Article
CAS
PubMed
Google Scholar
Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia. 2009;15:1014–21.
Article
CAS
PubMed
Google Scholar
Manco-Johnson MJ, Sanders J, Ewing N, Rodriguez N, Tarantino M, Humphries T. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia. 2013;19:727–35.
Article
CAS
PubMed
Google Scholar
Nijdam A, Foppen W, De Kleijn P, Mauser-Bunschoten EP, Roosendaal G, van Galen KP, Schutgens RE, van der Schouw YT, Fischer K. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thromb Haemost. 2016;115:931–8.
Article
PubMed
Google Scholar
Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7:413–20.
Article
CAS
PubMed
Google Scholar
Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001;7:392–6.
Article
CAS
PubMed
Google Scholar
De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14:931–8.
Article
PubMed
Google Scholar
Ho S, Gue D, McIntosh K, Bucevska M, Yang M, Jackson S. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia. Haemophilia. 2014;20:39–43.
Article
CAS
PubMed
Google Scholar
Fischer K, Steen Carlsson K, Petrini P, Holmstrom M, Ljung R, van den Berg HM, Berntorp E. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013;122:1129–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Epstein J, Xiong Y, Woo P, Li-McLeod J, Spotts G. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients. Haemophilia. 2012;18:187–92.
Article
CAS
PubMed
Google Scholar
Crivianu-Gaita V, Rivard GE, Carcao M, Teitel J, St-Louis J, Blanchette V, Pullenayegum E, Abad A, Feldman BM. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A. Haemophilia. 2016;22(5):e401–5.
Article
CAS
PubMed
Google Scholar
Remor E, Young NL, Von Mackensen S, Lopatina EG. Disease-specific quality-of-life measurement tools for haemophilia patients. Haemophilia. 2004;10 Suppl 4:30–4.
Article
PubMed
Google Scholar
Klamroth R, Pollmann H, Hermans C, Faradji A, Yarlas AS, Epstein JD, Ewenstein BM. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia. 2011;17:412–21.
Article
CAS
PubMed
Google Scholar